Peg-IFN alfa-2b

Phase 3Biologic

Merck & Co.

Peg-IFN alfa-2b is one of 84 biologic programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

MelanomaActive, not recruiting

Hepatitis CActive, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Hepatitis CPreclinical

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 2

GSK 257049

GSK

Phase 3

1 3

Peg-IFN alfa-2b

Merck & Co.

Phase 3

1 4

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 5

Intron a

Merck & Co.

Preclinical

4 6

Opdualag

Bristol-Myers Squibb

Preclinical

3 7

Naporafenib

EErasca, Inc.

Phase 3

1 8

Adjuvant Nivolumab

TThe Netherlands Cancer Institute

Phase 3

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

Talimogene Laherparepvec

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis5 trials

Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01678131·31 enrolled

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

Completed· Merck & Co. logo

Merck & Co.··NCT00736242·232 enrolled

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT01606800·45 enrolled

Show 2 more trials

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Completed·TTibotec BVBA·Phase 2·NCT00528528·166 enrolled

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Completed· Roche logo

Roche··NCT01447446·4,442 enrolled

Melanoma1 trial

Adjuvant PEG Intron in Ulcerated Melanoma

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01502696·1,200 enrolled

Hepatitis C1 trial

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

Terminated· Merck & Co. logo

Merck & Co.··NCT00725842·97 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Peg-IFN alfa-2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peg-IFN alfa-2b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peg-IFN alfa-2b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Peg-IFN alfa-2b

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis5 trials

Melanoma1 trial

Hepatitis C1 trial

References

Drug Info

Quick Facts

Related News